ChemicalBook Product Catalog API Antipyretic analgesics Antipyretic analgesics Acetaminophen

1/2

Acetaminophen NEW

$1.00 100KG

$5.00 25KG

$6.00 1KG

Min. Order1KG
Purity99%
Cas No103-90-2
Supply Abilityg-kg-tons, free sample is available
Update time2024-03-29

Henan Fengda Chemical Co., Ltd

1YR

China

Chemical Properties

Product Name	Acetaminophen
CAS No	103-90-2
EC-No
Min. Order	1KG
Purity	99%
Supply Ability	g-kg-tons, free sample is available
Release date	2024/03/29

1. Product information

Name	paracetamol
Synonym	More Synonyms

Description	Acetaminophen (paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic drug.
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> COX Research Areas >> Inflammation/Immunology Natural Products >> Phenylpropanoids
Target	COX-2:25.8 μM (IC50) COX-1:113.7 μM (IC50) Human Endogenous Metabolite
In Vitro	In vitro, acetaminophen elicites a 4.4-fold selectivity toward COX-2 inhibition (IC50 113.7 μM for COX-1; IC50 25.8 μM for COX-2). Following oral administration of the drug, maximal ex vivo inhibitions are 56% (COX-1) and 83% (COX-2). Acetaminophen plasma concentrations remaine above the in vitro IC50 for COX-2 for at least 5 h postadministration. Ex vivo IC50 values (COX-1: 105.2 μM; COX-2: 26.3 μM) of acetaminophen compared favorably with its in vitro IC50 values. In contrast to previous concepts, acetaminophen inhibited COX-2 by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors. However, a >95% COX-1 blockade relevant for suppression of platelet function is not achieved[1]. MTT assay shows that Acetaminophen (APAP) in a dose of 50 mM significantly (p<0.001) reduces cell viability to 61.5±6.65%. Interestingly, the significant (p<0.01) increase in cell viability to 79.7±2.47% is observed in the Acetaminophen/HV110 co-treated cells, compared to Acetaminophen treated cells[2].
In Vivo	Administering Acetaminophen (250 mg/kg, orally) to the mice causes significant (p<0.001) liver damage and necrosis of cells as evidenced by the elevated serum hepatic enzymes alanine aminotransferase (ALT), aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (γGT) compared with normal group. Conversely, effects of pretreatment with different doses of citral (125, 250, and 500 mg/kg) exhibited a significant (p<0.05) decrease in serum activities of ALT (91.79%, 93.07%, and 95.61%, resp.), AST (93.40%, 91.89%, and 96.52%, resp.), ALP (39.29%, 37.07%, and 59.80%, resp.), and γGT (92.83%, 91.59%, and 93.0%, resp.), when compared to the Acetaminophen group. Similar results were found in pretreatment with SLM on the activity of ALT (95.90%), AST (95.03%), ALP (70.52%), and γGT (92.69%)[3].
Cell Assay	Human hepatoma cell line HepG2 is cultured in low glucose DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL Penicillin and 100 μg/mL Streptomycin and 2 mM l-glutamine. The cells are maintained in 75 cm2 flasks at 37°C in a humidified atmosphere containing 5% CO2 and split at 80% confluence every 5 days. Cells are seeded in 24-well plate (2×105 cells) and incubated at 37°C overnight followed by cells pretreatment with complete DMEM containing high glucose concentration in order to downregulate autophagy. After 6 h, cells are treated with different concentrations of postbiotics obtained from Lactobacillus fermentum BGHV110 strain (HV110) in order to select appropriate dose for further experiments. Postbiotic is dissolved in complete DMEM medium and added to the cells in specific final concentration. In all other experiments seeded cells are treated with 50 mM Acetaminophen alone or co-treated with 50 mM Acetaminophen and selected dose of lyophilized HV110. To analyze autophagic flux, simultaneously with treatments, cells are exposed to lysosomotropic agent Chloroquine at a concentration of 25 μM, to inhibit autophagosome-lysosome fusion[2].
Animal Admin	Mice[3] Male Swiss mice (30-40 g) are used. The experimental animals are divided into six groups of five animals each. Firstly, each group receive orally during seven days the following treatment: Group I: the mice do not receive any treatment (normal). Group II: the mice receive citral vehicle (0.1% Tween 80 solution). Groups III-V: the mice are pretreated with citral at doses of 125, 250, and 500 mg/kg, respectively. Group VI: the mice are pretreated with the hepatoprotective standard drug Silymarin (SLM) (200 mg/kg). After this time, the animals fasted for 8 h and then receive oral Acetaminophen on the seventh day at a dose of 250 mg/kg in Groups II-VI. Group I orally receive saline that contained 0.1% Tween 80 solution (Acetaminophen vehicle). The stock solution is used as the first concentration of 50 mg/mL and after that is diluted in 0.1% Tween 80 solution to prepare the solutions of 25 and 12.5 mg/mL. After 12 h of Acetaminophen administration, serum samples and liver tissue are collected followed by biochemistry and histological analysis.
References	[1]. Hinz, B, et al. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J, 2008. 22(2): p. 383-90. [2]. Dini? M, et al. Lactobacillus fermentum Postbiotic-induced Autophagy as Potential Approach for Treatment ofAcetaminophen Hepatotoxicity. Front Microbiol. 2017 Apr 6;8:594. [3]. Uchida NS, et al. Hepatoprotective Effect of Citral on Acetaminophen-Induced Liver Toxicity in Mice. Evid Based Complement Alternat Med. 2017;2017:1796209.

Density	1.3±0.1 g/cm3
Boiling Point	387.8±25.0 °C at 760 mmHg
Melting Point	168-172 °C(lit.)
Molecular Formula	C₈H₉NO₂
Molecular Weight	151.163
Flash Point	188.4±23.2 °C
Exact Mass	151.063324
PSA	49.33000
LogP	0.34
Vapour Pressure	0.0±0.9 mmHg at 25°C
Index of Refraction	1.619
Storage condition	Store at RT
Water Solubility	14 g/L (20 ºC)

4-Acetamidophenol MSDS(Chinese)

CHEMICAL IDENTIFICATION

RTECS NUMBER :
AE4200000

CHEMICAL NAME :
Acetanilide, 4'-hydroxy-

CAS REGISTRY NUMBER :
103-90-2

BEILSTEIN REFERENCE NO. :
2208089

LAST UPDATED :
199806

DATA ITEMS CITED :
92

MOLECULAR FORMULA :
C8-H9-N-O2

MOLECULAR WEIGHT :
151.18

WISWESSER LINE NOTATION :
QR DMV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - child

DOSE/DURATION :
591 mg/kg/2D-I

TOXIC EFFECTS :
Liver - liver function tests impaired Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - aplastic anemia

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
4962 ug/kg

TOXIC EFFECTS :
Gastrointestinal - changes in structure or function of endocrine pancreas Liver - liver function tests impaired Blood - other changes

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - man

DOSE/DURATION :
714 mg/kg

TOXIC EFFECTS :
Liver - other changes

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - infant

DOSE/DURATION :
1440 mg/kg/6D

TOXIC EFFECTS :
Behavioral - irritability Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - body temperature increase

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human

DOSE/DURATION :
143 mg/kg

TOXIC EFFECTS :
Behavioral - general anesthetic

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - child

DOSE/DURATION :
360 mg/kg/2D

TOXIC EFFECTS :
Gastrointestinal - nausea or vomiting Liver - other changes Skin and Appendages - dermatitis, other (after systemic exposure)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - child

DOSE/DURATION :
801 mg/kg

TOXIC EFFECTS :
Behavioral - general anesthetic Gastrointestinal - nausea or vomiting Liver - other changes

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - man

DOSE/DURATION :
714 mg/kg

TOXIC EFFECTS :
Cardiac - EKG changes not diagnostic of specified effects

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human

DOSE/DURATION :
357 mg/kg

TOXIC EFFECTS :
Behavioral - anorexia (human) Behavioral - coma Gastrointestinal - nausea or vomiting

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
260 mg/kg

TOXIC EFFECTS :
Behavioral - coma Gastrointestinal - nausea or vomiting Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
490 mg/kg

TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Gastrointestinal - other changes Kidney, Ureter, Bladder - other changes

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - man

DOSE/DURATION :
143 mg/kg/24H-I

TOXIC EFFECTS :
Behavioral - anorexia (human) Liver - hepatitis (hepatocellular necrosis), zonal Liver - jaundice, other or unclassified

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
650 mg/kg

TOXIC EFFECTS :
Vascular - BP lowering not characterized in autonomic section Vascular - other changes Nutritional and Gross Metabolic - metabolic acidosis

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - child

DOSE/DURATION :
50 mg/kg

TOXIC EFFECTS :
Cardiac - other changes Lungs, Thorax, or Respiration - acute pulmonary edema Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
400 mg/kg

TOXIC EFFECTS :
Behavioral - coma Liver - liver function tests impaired Nutritional and Gross Metabolic - metabolic alkalosis

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
1944 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
1205 mg/kg

TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - tremor

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
338 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
367 mg/kg

TOXIC EFFECTS :
Behavioral - analgesia Nutritional and Gross Metabolic - body temperature decrease

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
310 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
2 gm/kg

TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Blood - changes in spleen Nutritional and Gross Metabolic - body temperature decrease

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
826 mg/kg

TOXIC EFFECTS :
Behavioral - analgesia

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - guinea pig

DOSE/DURATION :
2620 mg/kg

TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Behavioral - tremor

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Amphibian - frog

DOSE/DURATION :
50 mg/kg

TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - ataxia Lungs, Thorax, or Respiration - other changes

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Mammal - species unspecified

DOSE/DURATION :
512 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Unreported

SPECIES OBSERVED :
Mammal - species unspecified

DOSE/DURATION :
891 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
105 gm/kg/35D-C

TOXIC EFFECTS :
Liver - other changes Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
68 gm/kg/13W-C

TOXIC EFFECTS :
Liver - other changes Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
6080 mg/kg/19D-I

TOXIC EFFECTS :
Gastrointestinal - other changes Liver - changes in liver weight Blood - changes in leukocyte (WBC) count

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
1600 mg/kg/2D-I

TOXIC EFFECTS :
Liver - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - cytochrome oxidases (including oxidative phosphorylation)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
136 gm/kg/13W-C

TOXIC EFFECTS :
Liver - other changes Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
336 gm/kg/40W-C

TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), diffuse Liver - other changes Liver - changes in liver weight

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
164 gm/kg/78W-C

TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Kidney, Ureter, Bladder - tumors

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
135 gm/kg/77W-C

TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Liver - hepatitis (hepatocellular necrosis), zonal Liver - tumors

TYPE OF TEST :
TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
270 gm/kg/77W-C

TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors Endocrine - other changes

TYPE OF TEST :
TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
329 gm/kg/78W-C

TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Liver - tumors

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
650 mg/kg

SEX/DURATION :
female 29 week(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - Apgar score (human only) Reproductive - Effects on Newborn - other neonatal measures or effects Reproductive - Effects on Newborn - other postnatal measures or effects

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
417 mg/kg

SEX/DURATION :
female 20 week(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - hepatobiliary system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
1300 mg/kg

SEX/DURATION :
female 31-32 week(s) after conception

TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Effects on Newborn - other neonatal measures or effects

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
1500 mg/kg

SEX/DURATION :
female 8-19 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
12500 mg/kg

SEX/DURATION :
female 14 day(s) pre-mating female 1-11 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
1 gm/kg

SEX/DURATION :
female 3 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - other postnatal measures or effects

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
35 gm/kg

SEX/DURATION :
male 70 day(s) pre-mating

TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - other effects on male

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
25 mg/kg

SEX/DURATION :
male 1 day(s) pre-mating

TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
600 mg/kg

SEX/DURATION :
male 1 day(s) pre-mating

TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
2500 mg/kg

SEX/DURATION :
female 6-15 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
2500 mg/kg

SEX/DURATION :
female 6-15 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
2 gm/kg

SEX/DURATION :
female 1 day(s) pre-mating

TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility

TYPE OF TEST :
Micronucleus test

TYPE OF TEST :
Cytogenetic analysis

TYPE OF TEST :
Sister chromatid exchange

TYPE OF TEST :
Unscheduled DNA synthesis

TYPE OF TEST :
Micronucleus test

TYPE OF TEST :
DNA damage

TYPE OF TEST :
Unscheduled DNA synthesis

TYPE OF TEST :
Cytogenetic analysis

TYPE OF TEST :
Cytogenetic analysis

TYPE OF TEST :
Sister chromatid exchange

TYPE OF TEST :
Sex chromosome loss and nondisjunction

MUTATION DATA

TYPE OF TEST :
Sister chromatid exchange

TEST SYSTEM :
Rodent - hamster Lung

DOSE/DURATION :
1 mmol/L

REFERENCE :
MUTAEX Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1986- Volume(issue)/page/year: 3,51,1988 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 IARC Cancer Review:Group 3 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 TOXICOLOGY REVIEW JRPMAP Journal of Reproductive Medicine. (2 Jacklynn Ct., St. Louis, MO 63132) V.3- 1969- Volume(issue)/page/year: 12,27,1974 TOXICOLOGY REVIEW AUHPAI Australian Journal of Hospital Pharmacy. (B.R. Miller, POB 125, Heidelberg, Vic., Australia) V.1- 1971- Volume(issue)/page/year: 3(3),100,1973 TOXICOLOGY REVIEW CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 12,601,1978 TOXICOLOGY REVIEW NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information. Volume(issue)/page/year: PB282-666 TOXICOLOGY REVIEW OBGNAS Obstetrics and Gynecology. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.1- 1953- Volume(issue)/page/year: 58,57S,1981 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80396 No. of Facilities: 1829 (estimated) No. of Industries: 7 No. of Occupations: 14 No. of Employees: 9269 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80396 No. of Facilities: 1261 (estimated) No. of Industries: 7 No. of Occupations: 26 No. of Employees: 65107 (estimated) No. of Female Employees: 56260 (estimated)

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302-H315-H317-H319
Precautionary Statements	P280-P301 + P312 + P330-P305 + P351 + P338
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes	Xn
Risk Phrases	R22:Harmful if swallowed. R36/37/38:Irritating to eyes, respiratory system and skin . R52/53:Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment . R36/38:Irritating to eyes and skin . R40:Limited evidence of a carci
Safety Phrases	S26-S36-S61-S37/39
RIDADR	NONH for all modes of transport
WGK Germany	1
RTECS	AE4200000
HS Code	29242930

Precursor 0
DownStream 10	Previous 1/3 Next
CAS#:105326-63-4 N-[4-(quinolin-... CAS#:109690-44-0 [4-[2-(4-azaniu... CAS#:30824-21-6 4-Acetamidophen... CAS#:3273-78-7 Benzenamine,4,4...

HS Code	29242930

Characterization of a highly sensitive and selective novel trapping reagent, stable isotope labeled glutathione ethyl ester, for the detection of reactive metabolites.

J. Pharmacol. Toxicol. Methods 76 , 83-95, (2015)

Glutathione (GSH) trapping assays are widely used to predict the post-marketing risk for idiosyncratic drug reactions (IDRs) in the pharmaceutical industry. Although several GSH derivatives have been ...

Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury.

Sci. Rep. 5 , 8521, (2015)

Overdosing of the analgesic acetaminophen (APAP, paracetamol) is a major cause of acute liver injury. Whereas toxicity is initiated by hepatocyte necrosis, course of disease is regulated by mechanisms...

Simple and reliable HPLC method for the monitoring of methotrexate in osteosarcoma patients.

J. Chromatogr. Sci. 52(7) , 590-5, (2014)

Methotrexate (MTX) is a dihydrofolate reductase inhibitor that is used for the treatment of tumors and autoimmune diseases. Several automated binding assays are used in clinical practice and numerous ...

APAP

Calpol

NAPAP

p-acetaminophenol

Panadol

Tylenol

Exdol

Acetamide, N-(4-hydroxyphenyl)-

4-(Acetylamino)phenol

Acetamide, N-(p-hydroxyphenyl)-

Fevor

Acetanilide, 4'-hydroxy-